Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America.
The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.
The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 7, 24 | -0.02 Increased by +75.00% | -0.05 Increased by +60.00% |
| Aug 1, 24 | -0.10 Increased by +9.09% | -0.08 Decreased by -25.00% |
| May 8, 24 | -0.08 Increased by +50.00% | -0.11 Increased by +27.27% |
| Feb 29, 24 | 0.26 Increased by +116.67% | 0.17 Increased by +52.94% |
| Nov 8, 23 | -0.08 Increased by +42.86% | -0.12 Increased by +33.33% |
| Aug 2, 23 | -0.11 Increased by +42.11% | -0.15 Increased by +26.67% |
| May 10, 23 | -0.16 Decreased by -6.67% | -0.15 Decreased by -6.67% |
| Feb 23, 23 | 0.12 Increased by +33.33% | 0.04 Increased by +200.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 57.91 M Increased by +27.04% | -901.00 K Increased by +75.38% | Decreased by -1.56% Increased by +80.62% |
| Jun 30, 24 | 52.66 M Increased by +14.68% | -4.68 M Increased by +6.73% | Decreased by -8.89% Increased by +18.67% |
| Mar 31, 24 | 51.28 M Increased by +25.02% | -3.86 M Increased by +39.06% | Decreased by -7.53% Increased by +51.25% |
| Dec 31, 23 | 65.00 M Increased by +23.35% | 12.99 M Increased by +119.40% | Increased by +19.99% Increased by +77.88% |
| Sep 30, 23 | 45.58 M Increased by +18.24% | -3.66 M Increased by +44.35% | Decreased by -8.03% Increased by +52.93% |
| Jun 30, 23 | 45.92 M Increased by +23.96% | -5.02 M Increased by +43.24% | Decreased by -10.93% Increased by +54.21% |
| Mar 31, 23 | 41.02 M Increased by +13.70% | -6.34 M Increased by +8.28% | Decreased by -15.45% Increased by +19.33% |
| Dec 31, 22 | 52.69 M Increased by +10.72% | 5.92 M Increased by +30.61% | Increased by +11.24% Increased by +17.96% |